HR 7953
FAIR ACT
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 1:26 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
The FAIR ACT aims to speed up access to innovative medicines for life-threatening diseases in the United States by allowing the FDA to recognize approvals granted by trusted international regulatory authorities. Specifically, it establishes a ‘reciprocal marketing approval’ system where drugs already approved in countries like the UK, Canada, or the European Medicines Agency can be automatically considered approved in the U.S. The bill also includes provisions to streamline the process for conducting clinical trials in the U.S. based on approvals from these international bodies. It also includes a reporting requirement to assess the program's effectiveness and make recommendations for the future.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.